PL376217A1 - Sposób kardioprotekcji i neuroprotekcji przez dożylne podawanie fluorowcowanych lotnych środków znieczulających - Google Patents

Sposób kardioprotekcji i neuroprotekcji przez dożylne podawanie fluorowcowanych lotnych środków znieczulających

Info

Publication number
PL376217A1
PL376217A1 PL03376217A PL37621703A PL376217A1 PL 376217 A1 PL376217 A1 PL 376217A1 PL 03376217 A PL03376217 A PL 03376217A PL 37621703 A PL37621703 A PL 37621703A PL 376217 A1 PL376217 A1 PL 376217A1
Authority
PL
Poland
Prior art keywords
cardioprotection
neuroprotection
intravenous administration
ischemic event
halogenated volatile
Prior art date
Application number
PL03376217A
Other languages
English (en)
Other versions
PL219493B1 (pl
Inventor
Raul Trillo
Ralph Lessor
Satish Pejaver
Navneet Puri
Original Assignee
Baxter International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International, Inc. filed Critical Baxter International, Inc.
Publication of PL376217A1 publication Critical patent/PL376217A1/pl
Publication of PL219493B1 publication Critical patent/PL219493B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL376217A 2002-10-11 2003-10-09 Zastosowanie kompozycji zawierającej fluorowcowany lotny środek znieczulający oraz kompozycja zawierająca fluorowcowany lotny związek znieczulający do zastosowania w leczeniu pacjenta PL219493B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11

Publications (2)

Publication Number Publication Date
PL376217A1 true PL376217A1 (pl) 2005-12-27
PL219493B1 PL219493B1 (pl) 2015-05-29

Family

ID=32094122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376217A PL219493B1 (pl) 2002-10-11 2003-10-09 Zastosowanie kompozycji zawierającej fluorowcowany lotny środek znieczulający oraz kompozycja zawierająca fluorowcowany lotny związek znieczulający do zastosowania w leczeniu pacjenta

Country Status (19)

Country Link
US (1) US7999011B2 (pl)
EP (1) EP1558226B1 (pl)
JP (1) JP5210486B2 (pl)
KR (2) KR20120030598A (pl)
CN (2) CN1703209A (pl)
AT (1) ATE546136T1 (pl)
AU (1) AU2003282464B2 (pl)
BR (1) BR0314617A (pl)
CA (1) CA2500310C (pl)
DK (1) DK1558226T3 (pl)
ES (1) ES2382911T3 (pl)
HK (1) HK1079703A1 (pl)
IL (1) IL167472A (pl)
MX (1) MXPA05003741A (pl)
NZ (1) NZ539298A (pl)
PL (1) PL219493B1 (pl)
RU (1) RU2350323C2 (pl)
WO (1) WO2004032858A2 (pl)
ZA (1) ZA200502741B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
CA2663857C (en) * 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
DE112008002914A5 (de) * 2007-11-06 2010-09-30 B. Braun Melsungen Ag Einen hydrophoben Wirkstoff enthaltende wässrige Emulsionen
EP2244783B1 (en) 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
PL2244737T3 (pl) * 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CN109394689A (zh) * 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
RU2408396C1 (ru) * 2009-07-30 2011-01-10 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и федеральному развитию" Комбинированная двухсегментарная регионарная анестезия при выполнении каротидной эндартерэктомии у больных критической ишемией нижних конечностей и выраженным болевым синдромом
WO2011012283A1 (en) 2009-07-30 2011-02-03 University Of Zurich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
EP2723325A4 (en) 2011-06-24 2015-03-11 Vapogenix Inc NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
PL2968214T3 (pl) * 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe
ITMO20130075A1 (it) * 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
DE69429524T2 (de) * 1993-09-24 2002-08-08 The University Of British Columbia, Vancouver Aminocyclohexylester und ihre anwendung
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
DE60132337T2 (de) 2000-07-26 2009-02-12 Taro Pharmaceutical Industries Ltd. Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Also Published As

Publication number Publication date
HK1079703A1 (zh) 2006-04-13
ATE546136T1 (de) 2012-03-15
EP1558226A2 (en) 2005-08-03
DK1558226T3 (da) 2012-05-07
EP1558226A4 (en) 2008-04-02
NZ539298A (en) 2008-11-28
US20040127578A1 (en) 2004-07-01
WO2004032858A3 (en) 2004-09-23
IL167472A (en) 2013-10-31
KR20050056230A (ko) 2005-06-14
MXPA05003741A (es) 2005-06-17
KR20120030598A (ko) 2012-03-28
AU2003282464A1 (en) 2004-05-04
WO2004032858A2 (en) 2004-04-22
JP2006504740A (ja) 2006-02-09
US7999011B2 (en) 2011-08-16
BR0314617A (pt) 2005-08-02
KR101403264B1 (ko) 2014-06-02
CN102283821A (zh) 2011-12-21
ES2382911T3 (es) 2012-06-14
ZA200502741B (en) 2006-02-22
CA2500310A1 (en) 2004-04-22
CN1703209A (zh) 2005-11-30
RU2005114008A (ru) 2005-10-27
EP1558226B1 (en) 2012-02-22
RU2350323C2 (ru) 2009-03-27
JP5210486B2 (ja) 2013-06-12
AU2003282464B2 (en) 2010-02-25
CA2500310C (en) 2013-03-12
PL219493B1 (pl) 2015-05-29

Similar Documents

Publication Publication Date Title
Borgeat et al. Patient-controlled analgesia after major shoulder surgery: patient-controlled interscalene analgesia versus patient-controlled analgesia
RUBIN Intracordal injection of silicone in selected dysphonias
PL376217A1 (pl) Sposób kardioprotekcji i neuroprotekcji przez dożylne podawanie fluorowcowanych lotnych środków znieczulających
Ueda et al. A comparative study of sequential epidural bolus technique and continuous epidural infusion
JP2002500180A5 (pl)
KR100535554B1 (ko) 소아과 수술에서의 레보부피바카인의 용도
Credie et al. Effects of methadone on the minimum alveolar concentration of isoflurane in dogs
Arirudran et al. Local anesthetics in pediatric dental practice
Kulkarni et al. Painless anaesthesia in pediatric dentistry: an updated review
WO2003015690B1 (en) Method for treating primary insomnia
Barker et al. Femoral nerve blockade administered preclinically for pain relief in severe knee trauma is more feasible and effective than intravenous metamizole: a randomized controlled trial
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Padmanabhan et al. Dental Anesthesia: Can Needle-Free Injections Help
UA27230C2 (uk) Похідні андростану, заміщені по 16-му положенню четвертинною амонієвою групою, для використання як нервово-м'язових блокаторів та фармацевтична композиція, що здатна викликати нервово-м'язову блокаду
US4017619A (en) Anesthetic and sedative composition
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
Nagargoje et al. Recent advances in local anesthesia delivery systems: a review
Yaacob et al. The efficacy of xylocaine topical anaesthetic in reducing injection pain
Zhang et al. Evaluation of the intubating conditions and maintenance doses of rocuronium
Gupta et al. Intrathecal Administration of Bupivacaine and Bupivacaine With Different Doses of Clonidine For Post-operative Analgesia in Lower Abdominal and Lower Limb Surgeries–A Comparative Study
Arangannal et al. Intranasal Local Anaesthesia: A Recent Advancement in Pediatric Dentistry.
Goodman et al. Subcutaneous bupivacaine for treatment of spasticity: A case report
Bavisha et al. Comparison of patient-controlled and operator-controlled conscious sedation for restorative dentistry